<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CLEOCIN PEDIATRIC- clindamycin palmitate hydrochloride granule, for solution </strong><br>Pharmacia and Upjohn Company<br></p></div>
<h1>Cleocin Pediatric<span class="Sup">®</span><br> (clindamycin palmitate hydrochloride for oral solution, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PEDIATRIC and other antibacterial drugs, CLEOCIN PEDIATRIC should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
<p><span class="Italics">Not for Injection</span></p>
</div>
<div class="Warning">
<a name="Boxed_Warning"></a><a name="section-2"></a><p></p>
<h1>WARNING</h1>
<p class="First"><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C.difficile</span>.</p>
<p>Because clindamycin therapy has been associated with severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> which  may end fatally, it should be reserved for serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> where less toxic antimicrobial agents are inappropriate, as described in the <span class="Bold"><a href="#Indications_and_Usage">INDICATIONS AND USAGE</a></span> section. It should not be used in patients with nonbacterial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> such as most <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span>. <span class="Italics">C.difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C.difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C.difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C.difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Clindamycin palmitate hydrochloride is a water soluble hydrochloride salt of the ester of clindamycin and palmitic acid. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.</p>
<p>The structural formula is represented below:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45&amp;name=cleocin-01.jpg"></div>
<p>The chemical name for clindamycin palmitate hydrochloride is Methyl 7-chloro-6, 7, 8-trideoxy-6-(1-methyl-<span class="Italics">trans</span>-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-<span class="Italics">threo</span>-α-D-<span class="Italics">galacto</span>-octopyranoside 2-palmitate monohydrochloride.</p>
<p>CLEOCIN PEDIATRIC Flavored Granules contain clindamycin palmitate hydrochloride for reconstitution. Each 5 mL contains the equivalent of 75 mg clindamycin. Inactive ingredients: artificial cherry flavor, dextrin, ethylparaben, pluronic F68, simethicone, sucrose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="49489-8">
<a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Clindamycin inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome. It has activity against Gram-positive aerobes and anaerobes as well as -some Gram-negative anaerobes. Clindamycin is bacteriostatic. Cross-resistance between clindamycin and lincomycin is complete. Antagonism <span class="Italics">in vitro</span> has been demonstrated between clindamycin and erythromycin. Clindamycin inducible resistance has been identified in macrolide-resistant staphylococci and beta-hemolytic streptococci. Macrolide-resistant isolates of these organisms should be screened for clindamycin inducible resistance using the D-zone test.</p>
<p>Clindamycin has been shown to be active against most of the isolates of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, as described in the <span class="Bold"><a href="#Indications_and_Usage">INDICATIONS AND USAGE</a></span> section.</p>
<p><span class="Bold">Gram-positive aerobes</span></p>
<dl>
<dt> </dt>
<dd>
<span class="Italics">Staphylococcus aureus</span> (methicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</dd>
<dt> </dt>
<dd>
<span class="Italics">Streptococcus pneumoniae</span> (penicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</dd>
<dt> </dt>
<dd><span class="Italics">Streptococcus pyogenes</span></dd>
</dl>
<p><span class="Bold">Anaerobes</span></p>
<dl>
<dt> </dt>
<dd><span class="Italics">Prevotella melaninogenica</span></dd>
<dt> </dt>
<dd><span class="Italics">Fusobacterium necrophorum</span></dd>
<dt> </dt>
<dd><span class="Italics">Fusobacterium nucleatum</span></dd>
<dt> </dt>
<dd><span class="Italics">Peptostreptococcus anaerobius</span></dd>
<dt> </dt>
<dd><span class="Italics">Clostridium perfringens</span></dd>
</dl>
<p>At least 90% of the microorganisms listed below exhibit <span class="Italics">in vitro</span> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) less than or equal to the clindamycin susceptible MIC breakpoint for organisms of a similar type to those shown in Table 1. However, the efficacy of clindamycin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms <span class="Bold">has not been</span> established in adequate and well-controlled clinical trials.</p>
<p><span class="Bold">Gram-positive aerobes</span></p>
<dl>
<dt> </dt>
<dd>
<span class="Italics">Staphylococcus epidermidis</span> (methicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</dd>
<dt> </dt>
<dd><span class="Italics">Streptococcus agalactiae</span></dd>
<dt> </dt>
<dd><span class="Italics">Streptococcus anginosus</span></dd>
<dt> </dt>
<dd><span class="Italics">Streptococcus oralis</span></dd>
<dt> </dt>
<dd><span class="Italics">Streptococcus mitis</span></dd>
</dl>
<p><span class="Bold">Anaerobes</span></p>
<dl>
<dt> </dt>
<dd><span class="Italics">Prevotella intermedia</span></dd>
<dt> </dt>
<dd><span class="Italics">Prevotella bivia</span></dd>
<dt> </dt>
<dd><span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span></dd>
<dt> </dt>
<dd><span class="Italics">Micromonas ("Peptostreptococcus") micros</span></dd>
<dt> </dt>
<dd><span class="Italics">Finegoldia ("Peptostreptococcus") magna</span></dd>
<dt> </dt>
<dd><span class="Italics">Actinomyces israelii</span></dd>
<dt> </dt>
<dd><span class="Italics">Clostridium clostridioforme</span></dd>
<dt> </dt>
<dd><span class="Italics">Eubacterium lentum</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Susceptibility Testing Methods</h2>
<p class="First">When available, the clinical microbiology laboratory should provide cumulative <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.1"></a><p></p>
<h3>Dilution Techniques</h3>
<p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure based on dilution methods (broth, agar, or microdilution)<span class="Sup">3,4</span> or equivalent using standardized inoculum and concentrations of clindamycin. The MIC values should be interpreted according to the criteria provided in Table 1.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.2"></a><p></p>
<h3>Diffusion Techniques</h3>
<p class="First">Quantitative methods that require the measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The standardized procedure<span class="Sup">3,5</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 2 mcg of clindamycin to test the susceptibility of microorganisms to clindamycin. Reports from the laboratory providing results of the standard single-disk susceptibility test with a 2 mcg clindamycin disk should be interpreted according to the criteria in Table 1.</p>
<table width="90%">
<caption><span>Table 1. Susceptibility Interpretive Criteria for Clindamycin</span></caption>
<col align="left" valign="top" width="16%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<thead>
<tr class="First">
<th class="Rrule" align="center">Pathogen</th>
<th class="Botrule" align="center" colspan="6">Susceptibility Interpretive Criteria</th>
</tr>
<tr class="Botrule">
<th class="Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="3">Minimal Inhibitory Concentrations<br> (MIC in mcg/mL)</th>
<th class="Botrule" align="center" colspan="3">Disk Diffusion<br> (Zone Diameters in mm)</th>
</tr>
<tr class="Last">
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center">S</th>
<th class="Rrule" align="center">I</th>
<th class="Rrule" align="center">R</th>
<th class="Rrule" align="center">S</th>
<th class="Rrule" align="center">I</th>
<th align="center">R</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="7">NA=not applicable</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">
<span class="Italics">Staphylococcus</span> spp.</td>
<td class="Rrule" align="center">≤0.5</td>
<td class="Rrule" align="center">1–2</td>
<td class="Rrule" align="center">≥4</td>
<td class="Rrule" align="center">≥21</td>
<td class="Rrule" align="center">15–20</td>
<td align="center">≤14</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Italics">Streptococcus<br>pneumoniae</span><br>and other <span class="Italics">Streptococcus</span> spp.</td>
<td class="Rrule" align="center">
<br>≤0.25</td>
<td class="Rrule" align="center">
<br>0.5</td>
<td class="Rrule" align="center">
<br>≥1</td>
<td class="Rrule" align="center">
<br>≥19</td>
<td class="Rrule" align="center">
<br>16–18</td>
<td align="center">
<br>≤15</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">Anaerobic Bacteria</td>
<td class="Rrule" align="center">≤2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">≥8</td>
<td class="Rrule" align="center">NA</td>
<td class="Rrule" align="center">NA</td>
<td align="center">NA</td>
</tr>
</tbody>
</table>
<p>A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small, uncontrolled technical factors from causing major discrepancies in interpretation.</p>
<p>A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2>Quality Control</h2>
<p class="First">Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test.<span class="Sup">3,4,5,6</span> Standard clindamycin powder should provide the MIC ranges in Table 2. For the disk diffusion technique using the 2 mcg clindamycin disk the criteria provided in Table 2 should be achieved.</p>
<table width="90%">
<caption><span>Table 2. Acceptable Quality Control Ranges for Clindamycin to be Used in Validation of Susceptibility Test Results</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead>
<tr class="First">
<th class="Rrule" align="center">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span></th>
<th class="Botrule" align="center" colspan="2">Acceptable Quality Control Ranges</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentration</span> Range<br> (mcg/mL)</th>
<th align="center">Disk Diffusion Range<br> (Zone Diameters in mm)</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="3">NA=Not applicable</td></tr>
<tr class="Last"><td align="left" colspan="3">ATCC<span class="Sup">®</span> is a registered trademark of the American Type Culture Collection</td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left"><span class="Bold Italics">When Testing Aerobic Pathogens</span></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Italics">Staphylococcus aureus</span><br> ATCC 29213</td>
<td class="Rrule" align="center">0.06–0.25</td>
<td align="center">NA</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Italics">Staphylococcus aureus</span><br> ATCC 25923</td>
<td class="Rrule" align="center">NA</td>
<td align="center">24–30</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Italics">Streptococcus pneumoniae</span><br> ATCC 49619</td>
<td class="Rrule" align="center">0.03–0.12</td>
<td align="center">19–25</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="Bold Italics">When Testing Anaerobes</span></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Italics">Bacteroides fragilis</span><br> ATCC 25285</td>
<td class="Rrule" align="center">0.5–2</td>
<td align="center">NA</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Italics">Bacteroides thetaiotaomicron</span><br> ATCC 29741</td>
<td class="Rrule" align="center">2–8</td>
<td align="center">NA</td>
</tr>
<tr class="Botrule Last">
<td class="Rrule" align="left">
<span class="Italics">Eubacterium lentum</span><br> ATCC 43055</td>
<td class="Rrule" align="center">0.06–0.25</td>
<td align="center">NA</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4"></a><p></p>
<h2>Human Pharmacology</h2>
<p class="First">Blood level studies comparing clindamycin palmitate HCl  with clindamycin hydrochloride show that both drugs reach their peak active serum levels at the same time, indicating a rapid hydrolysis of the palmitate to the clindamycin.</p>
<p>Clindamycin is widely distributed in body fluids and tissues (including bones). Approximately 10% of the biological activity is excreted in the urine. The average serum half-life after doses of CLEOCIN PEDIATRIC is approximately two hours in pediatric patients.</p>
<p>Serum half-life of clindamycin is increased slightly in patients with markedly reduced renal function. Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum.</p>
<p>Serum level studies with clindamycin palmitate HCl in normal pediatric patients weighing 50–100 lbs given 2, 3 or 4 mg/kg every 6 hours (8, 12 or 16 mg/kg/day) demonstrated mean peak clindamycin serum levels of 1.24, 2.25 and 2.44 mcg/mL respectively, one hour after the first dose. By the fifth dose, the 6-hour serum concentration had reached equilibrium. Peak serum concentrations after this time would be about 2.46, 2.98 and 3.79 mcg/mL with doses of 8, 12 and 16 mg/kg/day, respectively.</p>
<p>Serum levels have been uniform and predictable from person to person and dose to dose. Multiple-dose studies in neonates and infants up to 6 months of age show that the drug does not accumulate in the serum and is excreted rapidly. Serum levels exceed the MICs for most indicated organisms for at least six hours following administration of the usually recommended doses of CLEOCIN PEDIATRIC in adults and pediatric patients.</p>
<p>No significant levels of clindamycin are attained in the cerebrospinal fluid, even in the presence of inflamed meninges.</p>
<p>Pharmacokinetic studies in elderly volunteers (61–79 years) and younger adults (18–39 years) indicate that age alone does not alter clindamycin pharmacokinetics (clearance, elimination half-life, volume of distribution, and area under the serum concentration-time curve) after IV administration of clindamycin phosphate.</p>
<p>After oral administration of clindamycin hydrochloride, elimination half-life is increased to approximately 4.0 hours (range 3.4 – 5.1 h) in the elderly compared to 3.2 hours (range 2.1 – 4.2 h) in younger adults; administration of clindamycin palmitate HCl resulted in a similar elimination  half-life value of about 4.5 hours in elderly subjects. However, the extent of absorption is not different between age groups and no dosage alteration is necessary for the elderly with normal hepatic function and normal (age-adjusted) renal function<span class="Sup">1</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Indications_and_Usage"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">CLEOCIN PEDIATRIC (clindamycin palmitate HCl) is indicated in the treatment of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible anaerobic bacteria.</p>
<p>Clindamycin is also indicated in the treatment of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, as described in the <a href="#Boxed_Warning">WARNING box</a>, before selecting clindamycin the physician should consider the nature of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the suitability of less toxic alternatives (e.g., erythromycin).</p>
<p><span class="Bold">Anaerobes:</span> Serious <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span> such as <span class="product-label-link" type="condition" conceptid="4209859" conceptname="Empyema">empyema</span>, anaerobic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="257010" conceptname="Abscess of lung">lung abscess</span>; serious skin and <span class="product-label-link" type="condition" conceptid="4320030" conceptname="Soft tissue infection">soft tissue infections</span>; <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>; intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span> such as <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> and intra-<span class="product-label-link" type="condition" conceptid="4326255" conceptname="Abdominal abscess">abdominal abscess</span> (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the female pelvis and genital tract such as <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span>, nongonococcal tubo-ovarian <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, pelvic <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span> and postsurgical vaginal cuff <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p><span class="Bold">Streptococci:</span> Serious <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span>; serious skin and <span class="product-label-link" type="condition" conceptid="4320030" conceptname="Soft tissue infection">soft tissue infections</span>.</p>
<p><span class="Bold">Staphylococci:</span> Serious <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span>; serious skin and <span class="product-label-link" type="condition" conceptid="4320030" conceptname="Soft tissue infection">soft tissue infections</span>.</p>
<p><span class="Bold">Pneumococci:</span> Serious <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span>.</p>
<p>Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>
<span class="Italics">In Vitro</span> Susceptibility Testing</h2>
<p class="First">A standardized disk testing procedure<span class="Sup">2</span> is recommended for determining susceptibility of aerobic bacteria to clindamycin. A description is contained in the CLEOCIN<span class="Sup">®</span> Susceptibility Disk (clindamycin) insert. Using this method, the laboratory can designate isolates as resistant, intermediate, or susceptible. Tube or agar dilution methods may be used for both anaerobic and aerobic bacteria. When the directions in the CLEOCIN<span class="Sup">®</span> Susceptibility Powder insert are followed, an MIC (minimal inhibitory concentration) of 1.6 mcg/mL may be considered susceptible; MICs of 1.6 to 4.8 mcg/mL may be considered intermediate and MICs greater than 4.8 mcg/mL may be considered resistant.</p>
<p>CLEOCIN Susceptibility Disks 2 mcg. See package insert for use.</p>
<p>CLEOCIN Susceptibility Powder 20 mg. See package insert for use.</p>
<p>For anaerobic bacteria the minimal inhibitory concentration (MIC) of clindamycin can be determined by agar dilution and broth dilution (including microdilution) techniques. If MICs are not determined routinely, the disk broth method is recommended for routine use. THE KIRBY-BAUER DISK DIFFUSION METHOD AND ITS INTERPRETIVE STANDARDS ARE NOT RECOMMENDED FOR ANAEROBES.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PEDIATRIC and other antibacterial drugs, CLEOCIN PEDIATRIC should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This drug is contraindicated in individuals with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to preparations containing clindamycin or lincomycin.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">See <a href="#Boxed_Warning">WARNING box</a>.</p>
<p><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including CLEOCIN PEDIATRIC (Clindamycin Palmitate HCL) , and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>. 						</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated. </p>
<p>A careful inquiry should be made concerning previous sensitivities to drugs and other allergens.</p>
<p><span class="Italics">Usage in <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span></span>: Since clindamycin does not diffuse adequately into the cerebrospinal fluid, the drug should not be used in the treatment of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Review of experience to date suggests that a subgroup of older patients with associated severe illness may tolerate <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> less well. When clindamycin is indicated in these patients, they should be carefully monitored for change in bowel frequency.</p>
<p>CLEOCIN PEDIATRIC (clindamycin palmitate HCl) should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>CLEOCIN PEDIATRIC should be prescribed with caution in <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopic</span> individuals.</p>
<p>Indicated surgical procedures should be performed in conjunction with antibiotic therapy.</p>
<p>The use of CLEOCIN PEDIATRIC occasionally results in overgrowth of nonsusceptible organisms-particularly yeasts. Should <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> occur, appropriate measures should be taken as indicated by the clinical situation.</p>
<p>Clindamycin dosage modification may not be necessary in patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. In patients with moderate to severe liver disease, prolongation of clindamycin half-life has been found. However, it was postulated from studies that when given every eight hours, accumulation should rarely occur. Therefore, dosage modification in patients with liver disease may not be necessary. However, periodic liver enzyme determinations should be made when treating patients with severe liver disease.</p>
<p>Prescribing CLEOCIN PEDIATRIC in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including CLEOCIN PEDIATRIC should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When CLEOCIN PEDIATRIC is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by CLEOCIN PEDIATRIC or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">During prolonged therapy, periodic liver and kidney function tests and blood counts should be performed.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.</p>
<p>Antagonism has been demonstrated between clindamycin and erythromycin <span class="Italics">in vitro</span>. Because of possible clinical significance, these two drugs should not be administered concurrently.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential. Genotoxicity tests performed included a rat micronucleus test and an Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> reversion test. Both tests were negative.</p>
<p>Fertility studies in rats treated orally with up to 300 mg/kg/day (approximately 1.6 times the highest recommended adult human oral dose based on mg/m<span class="Sup">2</span>) revealed no effects on fertility or mating ability.</p>
<p>In oral embryo fetal development studies in rats and subcutaneous embryo fetal development studies in rats and rabbits, no developmental toxicity was observed except at doses that produced maternal toxicity.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.6"></a><p></p>
<h2>Pregnancy: Teratogenic Effects</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.6.1"></a><p></p>
<h3>Pregnancy Category B</h3>
<p class="First">Oral and subcutaneous reproductive toxicity studies in rats and rabbits revealed no evidence of impaired fertility or harm to the fetus due to clindamycin, except at doses that caused maternal toxicity. Animal reproduction studies are not always predictive of human response.</p>
<p>In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities.</p>
<p>Clindamycin should be used during the first trimester of pregnancy only if clearly needed. There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Clindamycin has been reported to appear in breast milk in the range of 0.7 to 3.8 mcg/mL. Because of the potential for serious adverse reactions in nursing infants, clindamycin should not be taken by nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">When CLEOCIN HCl is administered to the pediatric population (birth to 16 years), appropriate monitoring of organ system functions is desirable.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of clindamycin did not include sufficient numbers of patients age 65 and over to determine whether they respond differently from younger patients. However, other reported clinical experience indicates that antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (due to <span class="Italics">Clostridium difficile</span>) seen in association with most antibiotics occur more frequently in the elderly (&gt;60 years) and may be more severe. These patients should be carefully monitored for the development of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Pharmacokinetic studies with clindamycin have shown no clinically important differences between young subjects (18–39 years) and elderly subjects (61–79 years) with normal hepatic function and normal (age-adjusted) renal function after oral or intravenous administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following reactions have been reported with the use of clindamycin.</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (see <span class="Bold"><a href="#Boxed_Warning">WARNING box</a></span>). The onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibacterial treatment (see <span class="Bold"><a href="#Warnings">WARNINGS</a></span>). An unpleasant or metallic taste occasionally has been reported after oral administration.</p>
<p><a name="Hypersensitivity_Reactions"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:</span> Generalized mild to moderate morbilliform-like (maculopapular) <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> are the most frequently reported adverse reactions. <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">Vesiculobullous rashes</span>, as well as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, have been observed during drug therapy. Rare instances of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, some resembling <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and a few cases of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have also been reported. <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">Acute Generalised Exanthematous Pustulosis</span> (<span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">AGEP</span>). <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span>.</p>
<p><span class="Italics">Skin and Mucous Membranes:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, and rare instances of <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> have been reported. (See <span class="Italics"><a href="#Hypersensitivity_Reactions"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></span>.)</p>
<p><span class="Italics">Liver:</span> <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> and abnormalities in liver function tests have been observed during clindamycin therapy.</p>
<p><span class="Italics">Renal:</span> Although no direct relationship of clindamycin to renal damage has been established, renal dysfunction as evidenced by <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and/or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> has been observed in rare instances.</p>
<p><span class="Italics">Hematopoietic:</span> Transient <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>) and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> have been reported. Reports of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> have been made. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of the foregoing.</p>
<p><span class="Italics">Immune system</span>: Drug reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS)</p>
<p><span class="Italics">Musculoskeletal:</span> Rare instances of <span class="product-label-link" type="condition" conceptid="4025831" conceptname="Arthritis mutilans">polyarthritis</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Significant mortality was observed in mice at an intravenous dose of 855 mg/kg and in rats at an oral or subcutaneous dose of approximately 2618 mg/kg. In the mice, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> were observed. Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">If significant <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs during therapy, this antibiotic should be discontinued (see <span class="Bold"><a href="#Boxed_Warning">WARNING box</a></span>).</p>
<p>Concomitant administration of food does not adversely affect the absorption of clindamycin palmitate HCl contained in CLEOCIN PEDIATRIC Flavored Granules.</p>
<p>Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: 8–12 mg/kg/day (4–6 mg/lb/day) divided into 3 or 4 equal doses.</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: 13–16 mg/kg/day (6.5–8 mg/lb/day) divided into 3 or 4 equal doses.</p>
<p>More severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: 17–25 mg/kg/day (8.5–12.5 mg/lb/day) divided into 3 or 4 equal doses.</p>
<p>In pediatric patients weighing 10 kg or less, ½ teaspoon (37.5 mg) three times a day should be considered the minimum recommended dose.</p>
<p>Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to anaerobic bacteria are usually treated with CLEOCIN PHOSPHATE<span class="Sup">®</span> Sterile Solution. However, in clinically appropriate circumstances, the physician may elect to initiate treatment or continue treatment with CLEOCIN PEDIATRIC.</p>
<p><span class="Bold">NOTE:</span> In cases of β-hemolytic <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, treatment should be continued for at least 10 days.</p>
<p><span class="Bold">Reconstitution Instructions:</span> When reconstituted with water as follows, each 5 mL (teaspoon) of solution contains clindamycin palmitate HCl equivalent to 75 mg clindamycin.</p>
<p>Reconstitute bottles of 100 mL with <span class="Bold">75 mL</span> of water. Add a large portion of the water and shake vigorously; add the remainder of the water and shake until the solution is uniform.</p>
<p><span class="Bold">Storage Conditions:</span> Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].</p>
<p>Do <span class="Bold">NOT</span> refrigerate the reconstituted solution; when chilled, the solution may thicken and be difficult to pour. The solution is stable for 2 weeks at room temperature.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">CLEOCIN PEDIATRIC Flavored Granules for oral solution is available in bottles of 100 mL (NDC 0009-0760-04).</p>
<p>When reconstituted as directed, each bottle yields a solution containing 75 mg of clindamycin per 5 mL.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-12"></a><p></p>
<h1>ANIMAL TOXICOLOGY</h1>
<p class="First">One year oral toxicity studies in Spartan Sprague-Dawley rats and beagle dogs at dose levels up to 300 mg/kg/day (approximately 1.6 and 5.4 times the highest recommended adult human oral dose based on mg/m<span class="Sup">2</span>, respectively) have shown clindamycin to be well tolerated. No appreciable difference in pathological findings has been observed between groups of animals treated with clindamycin and comparable control groups. Rats receiving clindamycin hydrochloride at 600 mg/kg/day (approximately 3.2 times the highest recommended adult human oral dose based on mg/m<span class="Sup">2</span>) for 6 months tolerated the drug well; however, dogs dosed at this level (approximately 10.8 times the highest recommended adult human oral dose based on mg/m<span class="Sup">2</span>) <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomited</span>, would not eat, and lost weight.</p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-13"></a><p></p>
<h1>References</h1>
<ol>
<li>Smith RB, Phillips JP: Evaluation of CLEOCIN HCl and CLEOCIN Phosphate in an Aged Population. Upjohn TR 8147-82-9122-021, December 1982.</li>
<li>Bauer AW, Kirby WMM, Sherris JC, Turck M: Antibiotic susceptibility testing by a standardized single disk method. <span class="Italics">Am J. Clin. Path.</span>, <span class="Bold">45</span>:493–496, 1966.<br>Standardized Disk Susceptibility Test, <span class="Italics">Federal Register</span>, <span class="Bold">37</span>:20527-29, 1972.</li>
<li>CLSI. <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fifth Informational Supplement</span> – CLSI document M 100-S25. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.</li>
<li>CLSI. <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard</span> – Tenth Edition. CLSI document M07-A10. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.</li>
<li>CLSI. <span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard</span> – Twelfth Edition. CLSI document M02-A12. Wayne, PA: Clinical and Laboratory Standards Institute; 2015. </li>
<li>CLSI. <span class="Italics">Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard</span> – Eighth Edition. CLSI document M11-A8. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<h1></h1>
<p class="First">This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com.</p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45&amp;name=cleocin-02.jpg"></p>
<p>LAB-0041-11.0</p>
<p>June 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 mL Bottle Label</h1>
<p class="First">NDC 0009-0760-04</p>
<p><span class="Bold Italics">Pfizer</span></p>
<p><span class="Bold">Cleocin Pediatric</span><span class="Sup">®</span><br>clindamycin palmitate<br>hydrochloride for oral<br>solution, USP</p>
<p>When reconstituted each 5 mL contains</p>
<p><span class="Bold">75 mg*</span></p>
<p>100 mL (when mixed)<br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 mL Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45&amp;name=cleocin-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 mL Bottle Carton</h1>
<p class="First">NDC 0009-0760-04</p>
<p><span class="Bold Italics">Pfizer</span></p>
<p><span class="Bold">Cleocin<br>Pediatric</span><span class="Sup">®</span><br>clindamycin<br>palmitate<br>hydrochloride for<br>oral solution, USP</p>
<p>When reconstituted each<br>5 mL contains</p>
<p><span class="Bold">75 mg*</span></p>
<p>100 mL (when mixed)<br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 mL Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45&amp;name=cleocin-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CLEOCIN PEDIATRIC 		
					</strong><br><span class="contentTableReg">clindamycin palmitate hydrochloride granule, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0009-0760</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLINDAMYCIN PALMITATE HYDROCHLORIDE</strong> (CLINDAMYCIN) </td>
<td class="formItem">CLINDAMYCIN</td>
<td class="formItem">75 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ETHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DIMETHICONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLOXAMER 188</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ICODEXTRIN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0009-0760-04</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA062644</td>
<td class="formItem">04/17/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pharmacia and Upjohn Company
							(829076566)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent Pharma Solutions, LLC</td>
<td class="formItem"></td>
<td class="formItem">829672745</td>
<td class="formItem">ANALYSIS(0009-0760), MANUFACTURE(0009-0760)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmacia and Upjohn Company</td>
<td class="formItem"></td>
<td class="formItem">829076566</td>
<td class="formItem">ANALYSIS(0009-0760), API MANUFACTURE(0009-0760), LABEL(0009-0760), PACK(0009-0760)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>233a84e6-868f-4d40-85b7-e6a299f4a1d5</div>
<div>Set id: 1ef87b6c-9d32-44ac-8c55-8bf01424cc45</div>
<div>Version: 9</div>
<div>Effective Time: 20150605</div>
</div>
</div> <div class="DistributorName">Pharmacia and Upjohn Company</div></p>
</body></html>
